IMAST 2019: Industry sponsored disc replacement trials should be treated with “caution”

Fernando Techy (Johnstown, USA), speaks to BLearning at IMAST 2019 (17 –20 July, Amsterdam, The Netherlands) about longer-term trials of disc replacement which, according to Techy has shown that “we are having less re-operations with disc replacement compared to fusion” and that “disk replacement does protect the adjacent levels in the long run”.

However, the key takeaway, says Techy is that the “vast majority” of these trials are industry sponsored. As such, Techy notes that there is “caution from the spine surgery community” that perhaps the differences between disc replacement and fusion in protecting the adjacent levels is “not as large as these studies have shown”. “We have to be very careful on how we read these studies” and any “potential biases” that could occur, he adds.

Techy believes that both disc replacement and fusion are “excellent” surgeries but that the key to treatment is “patient selection”. Disc replacement is in general indicated in younger patients with fewer levels, no deformity, no instability, no facet disease and less then 50% of disc height loss, he adds.

Techy, Fernando

Fernando Techy is a spine surgeon at the ClinTech Center for Spine Health. He previously worked as Director of Research at the Orthopaedic Stem Cell Institute and Rocky Mountain Associates. For three years he was also a Professor of Clinical Orthopaedics and Spine Surgery at the University of Illinois in Chicago.

Add comment

Editor’s Spinal Pick

    Subscribeto receive the very best in medical videos